Phase 2 N=621 Study of Cyclosporine in Post-LASIK Patients
Laser In Situ Keratomileusis
Primary: Time to Cure — 189.0; 194.0; 189.0 Days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
Perennial Allergic Rhinoconjunctivitis · House Dust Mite Allergy
Primary: Conjunctival Provocation Test (CPT) With House Dust Mite Allergen Solutions. Change of Median Individual Allergen Tolerance Compared to Baseline (Factor of Increase in…
Phase 3 N=509 Pregabalin Versus Levetiracetam In Partial Seizures
Partial Seizures
Primary: Proportion of Participants With Response to Treatment — 0.59; 0.59 proportion of participants
Phase 3 N=100 Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)
Anesthesia
Primary: Residual Neuromuscular Blockade Evidenced by T4/T1 Ratio at the Time of Tracheal Extubation — 1.02; 0.78 T4/T1 Ratio
Phase 2 N=130 Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation
Kidney Diseases · Kidney Transplantation · Kidney Transplant
Primary: The Difference in Linear Growth by Treatment Assignment at 1 Year Post Kidney Transplantation — 0.37; 0.35 Standard Deviation Score (SDS) — p=0.79
Phase 3 N=15 Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
Gastric Cancer
Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months
Phase 3 N=49 Randomized Trial of Inhaled Nitric Oxide to Augment Tissue Perfusion in Sepsis
Sepsis
Primary: Change in the Sequential Organ Failure Assessment (SOFA) Score
Phase 2 N=29 Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer · Stage III Ovarian Epithelial Cancer
Primary: Proportion of Patients Who Experience a Confirmed Response According to Modified RECIST Criteria. — 0.071; 0; 0; 0 proportion of participants
Phase 3 N=326 Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
Pseudobulbar Affect (PBA)
Primary: PBA Episode Rate Ratio (Post/Pre), Regression Adjusted — 0.247; 0.237; 0.465 Unit-free (ratio of episodes/week) — p=<0.0001
Phase 4 N=888 Pharmacogenomic Evaluation of Antihypertensive Responses
Hypertension
Primary: Blood Pressure Response (Delta BP (After 18 Weeks of Medication - Baseline)). — -12.06; -13.33 mmHg
Phase 3 N=20 Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)
Allergic Rhinitis
Primary: Change in Sneezing Symptom — 1; 1 sneezes
Phase 2 N=35 Metronidazole for Pulmonary Tuberculosis (South Korea)
Tuberculosis · Multi-Drug Resistant Tuberculosis
Primary: Changes in TB Lesion Sizes Using High Resolution Computed Tomography (HRCT). — 8.11; 10.08; 6.64; 7.24 reader score
Phase 2 N=39 Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) · Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Primary: The Number of Confirmed Disease Response: Complete Response (CR), Partial Response (PR), and Hematologic Improvement (HI). A Confirmed Response is Defined to be an…
Phase 2 N=44 Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Progression-free Survival at 6 Months — 0; 29 percentage of patients
Phase 2 N=63 Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumor
Primary: Rate of Disease Progression at 2 Years — 13.8 percentage of participants